DEF: Dual Strategy Fuels Growth: Company Eyes Massive Bitcoin Treasury and New Healthcare Frontiers

A company outlines its transformative strategy, combining aggressive Bitcoin accumulation with the launch of a new healthcare subsidiary, while seeking shareholder approval for significant capital raising flexibility.

Summary

• The company will hold its 2025 Annual Meeting of Stockholders virtually on Friday, September 5, 2025, at 9:00 a.m. Pacific Daylight Time.
• 2024 was a transformational year, marked by the adoption of Bitcoin (BTC) as the primary treasury reserve asset in May 2024, making it the second U.S. public company to do so.
• As of July 16, 2025, the company owns 4,846 Bitcoins, valued at over $578 million, and has generated a positive Bitcoin Yield of 298% since adoption.
• Since adopting the Bitcoin treasury strategy through July 16, 2025, the company's stock has appreciated 83%, significantly outperforming the S&P 500's 18% gain.
• Bitcoin has been accumulated using cash flows from operating business, proceeds from equity and convertible debt issuances, and monetization of a minority investment.
• The company announced long-term BTC accumulation targets: 10,000 BTC by the end of 2025, 42,000 BTC by the end of 2026, and 105,000 BTC by the end of 2027.
• The healthcare business generated record cash of $24 million in 2024, despite regulatory headwinds.
• In June 2025, the company launched CardioVanta, Inc., a wholly owned subsidiary focused on early detection of heart failure and cardiac arrhythmia monitoring, structured as a high-margin, software-as-a-service (SAAS) business model.
• CardioVanta will seek capital from outside investors to fund its initial capital needs, targeting multibillion-dollar markets projected to grow substantially.
• The company will continue marketing its flagship QuantaFlo device and software for early detection of peripheral artery disease.
• Shareholders will vote on proposals to increase authorized common stock from 50,000,000 shares to 210,000,000 shares and to authorize the issuance of 42,000,000 shares of blank-check preferred stock.
• As of June 30, 2025, there were 13,688,405 shares of common stock issued and outstanding, with 31,158,933 shares remaining available for future issuance from the current authorization.
• Net income was $40.9 million in 2024, up from $20.6 million in 2023 and $14.3 million in 2022.
• Audit fees for 2024 were $807,658, and audit-related fees were $28,016.

Sentiment

Score: 8

Explanation: The document conveys a highly positive and ambitious outlook, driven by a successful Bitcoin treasury strategy and a new, promising healthcare venture. Strong financial performance metrics (stock appreciation, Bitcoin yield, cash generation, net income growth) are highlighted. While risks associated with capital raises and market volatility are acknowledged, the overall tone is confident and forward-looking, indicating significant growth potential.

Positives

• Successfully adopted Bitcoin as a primary treasury asset, accumulating 4,846 BTC valued at over $578 million as of July 16, 2025.
• Generated a significant positive Bitcoin Yield of 298% since the strategy's adoption in May 2024.
• Stock has appreciated 83% since adopting the Bitcoin treasury strategy, significantly outperforming the S&P 500's 18% gain over the same period.
• Achieved record cash generation of $24 million from healthcare business operations in 2024.
• Launched CardioVanta, Inc., a new wholly owned subsidiary targeting multibillion-dollar, growing markets in early heart failure detection and cardiac arrhythmia monitoring with a high-margin SAAS model.
• Demonstrated strong conviction in Bitcoin's long-term investment potential, aiming to build one of the largest Bitcoin treasuries globally.
• Expanded stockholder base dramatically from approximately 11,000 in 2023 to over 32,000 currently.
• Strategic additions to the Board and management team, including Natalie Brunell (Board) and Joe Burnett (Director of Bitcoin Strategy), strengthening Bitcoin expertise.
• Proposals to increase authorized common stock and authorize blank-check preferred stock provide essential flexibility for future capital raises and strategic initiatives, including Bitcoin accumulation.

Negatives

• The medical device and software business faces regulatory headwinds.
• The new CardioVanta subsidiary will seek capital from outside investors, indicating a need for external funding for its growth.
• The proposed increase in authorized common stock and authorization of blank-check preferred stock could lead to dilution of existing common stockholders' equity interests and voting rights.
• The authorization of additional shares could have an anti-takeover effect, potentially discouraging bids for the company at a premium over market price.

Risks

• Regulatory headwinds in the medical device and software business could impact future performance.
• The success of the Bitcoin treasury strategy is subject to the volatility of Bitcoin prices and market conditions, which could affect capital raising and accumulation plans.
• Insufficient unissued and unreserved authorized shares of common stock could prevent the company from raising future capital opportunistically without delays from seeking stockholder approval.
• A lack of sufficient authorized common stock could adversely impact the ability to attract, retain, and motivate highly qualified personnel through equity incentive opportunities.
• Issuance of additional common stock could dilute the earnings per share and voting rights of current common stockholders.
• The issuance of preferred stock could dilute equity interests and earnings per share, potentially have superior voting rights, affect dividends, and reduce liquidation proceeds for common stockholders.
• The authorization of additional common and preferred stock could serve as an anti-takeover measure, potentially discouraging unsolicited takeover attempts or bids at a premium.

Future Outlook

The company is determined to build one of the largest Bitcoin treasuries in the world, with ambitious accumulation targets of 10,000 BTC by end of 2025, 42,000 BTC by end of 2026, and 105,000 BTC by end of 2027. It is also looking to new areas of growth in healthcare, leveraging its history in medical devices and software, with the launch of CardioVanta, Inc. This new subsidiary will focus on early detection of heart failure and cardiac arrhythmia monitoring, structured as a SAAS business, and will seek outside capital to validate its long-term value and fund initial needs. The company aims to become a dual-pronged powerhouse in the Bitcoin and medical technology sectors, empowering individuals with monetary freedom and cutting-edge healthcare solutions.

Management Comments

• "2024 was a transformational year for Semler Scientific."
• "We have strong conviction in Bitcoins long-term investment potential. We consider it digital gold and we believe that Bitcoin has significant upside when considering its massive discount to the value of gold."
• "With this confidence, we are determined to build one of the largest Bitcoin treasuries in the world."
• "This exciting strategic plan aims to enhance our ability to combat chronic diseases, save more lives, and increase our Bitcoin holdings. It represents a major opportunity for us to drive stockholder value and establish Semler Scientific as a dual-pronged powerhouse in the Bitcoin and medical technology sectors."
• "And it supports our long-term mission to empower individuals with both monetary freedom and cutting-edge healthcare solutions that improve access to early, preventative care."

Industry Context

The company's strategic shift into Bitcoin treasury management positions it uniquely among U.S. public companies, aligning with a growing trend of corporate Bitcoin adoption. Simultaneously, its expansion into early heart failure detection and cardiac arrhythmia monitoring through CardioVanta, Inc. taps into a rapidly expanding multi-billion dollar healthcare market. This market growth is driven by rising cardiovascular disease prevalence, advancements in technology like artificial intelligence, an aging global population, and increasing adoption of wearable and remote monitoring solutions, indicating a strong alignment with prevailing healthcare technology trends.

Comparison to Industry Standards

• The company became the second U.S. public company to adopt a Bitcoin treasury strategy, placing it among the leading corporate holders of Bitcoin in the United States.
• The 83% stock appreciation since adopting the Bitcoin strategy significantly outperformed the S&P 500's 18% gain over the same period, indicating strong relative performance compared to a broad market index.
• The target markets for CardioVanta (early detection of heart failure and cardiac arrhythmia monitoring) are estimated in the multibillion-dollar range and are projected to grow substantially, aligning with high-growth segments within the healthcare technology industry.

Management Changes

Corporate Governance

Related Party Transactions

• Cooperation Agreement: On April 19, 2023, entered into an agreement with Eric Semler and William H.C. Chang (each beneficial owners of >5% of common stock) to increase board size, appoint them as directors, appoint Mr. Semler as chairperson, and appoint them to the nominating and corporate governance committee. The agreement included voting commitments and non-disparagement provisions.
• Warrant Repurchase: On May 17, 2023, acquired outstanding warrants to acquire 76,875 shares of common stock from the chief executive officer for $1.9 million in cash. The warrants were subsequently cancelled.
• Executive Chairperson Consulting: On June 25, 2025, engaged Eric Semler (Executive Chairman) as an at-will consultant to provide additional services related to the Bitcoin treasury strategy, with cash compensation of $30,000 per month.

Stakeholder Impact

• Shareholders: Potential for significant value creation through the Bitcoin treasury strategy and the new CardioVanta healthcare business. However, face potential dilution of equity interests and voting rights due to proposed increases in authorized common and preferred stock. The proposals aim to provide financial flexibility for growth, which could benefit long-term shareholders.
• Employees: Continued opportunities for equity incentives under the 2024 Stock Option and Incentive Plan, which is crucial for attracting, retaining, and motivating highly qualified personnel. The launch of CardioVanta may create new employment opportunities.
• Customers: Continued access to the flagship QuantaFlo device for peripheral artery disease detection, and future access to new early detection and monitoring solutions from CardioVanta for heart failure and cardiac arrhythmia.
• Creditors: The company has utilized convertible debt issuances to fund its Bitcoin accumulation, indicating a reliance on various financing instruments which impacts creditors.

Next Steps

• Hold the 2025 Annual Meeting of Stockholders virtually on September 5, 2025, for shareholder votes on key proposals.
• Shareholders are encouraged to vote on the election of William H.C. Chang as a Class I director, advisory approval of executive compensation, increase in authorized common stock, authorization of blank-check preferred stock, and ratification of BDO USA, P.C. as the independent auditor.
• If approved by stockholders, the board of directors will have the authority to effect the increase in authorized common stock and/or preferred stock.
• CardioVanta, Inc. will seek capital from outside investors to validate its long-term value and fund initial capital needs.
• Continue marketing the flagship QuantaFlo device and software for early detection of peripheral artery disease.
• Work towards long-term Bitcoin accumulation targets: 10,000 BTC by end of 2025, 42,000 BTC by end of 2026, and 105,000 BTC by end of 2027.
• Final voting results from the annual meeting will be published in a current report on Form 8-K within four business days after the meeting.

Key Dates

Recommendation

Keywords

Bitcoin, cryptocurrency, medical devices, healthcare technology, heart failure, cardiac arrhythmia, SAAS, treasury strategy, SEC filing, proxy statement, corporate governance, capital raise, stock authorization, preferred stock, QuantaFlo, CardioVanta